



REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2025

The trustees present their report with the financial statements of the charity for the year ended 31 March 2025 and have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

About PLANETS

PLANETS Cancer Charity helps patients with pancreatic, liver, colorectal, gastric, oesophageal and neuroendocrine cancer by funding patient support groups, innovative treatments and research. Since 2011 we have raised just over £2.5 million.

PLANETS is dedicated to serving the needs of our regional population which extends from Lyme Regis to Bognor Regis and provides specialist cancer services to the four million people who live across Hampshire, Wiltshire, Dorset, the Isle of Wight, the Channel Islands and West Sussex.

Vision

Transforming cancer care in the south through our 'family' of patients, supporters and healthcare professionals to deliver world leading innovation, research and support for those affected by cancer within the PLANETS community.

Our ethos is one of inclusivity, where doctors, nurses, patients, family members, other healthcare workers and supporters all recognise each other's contributions and work together with a shared vision. In line with our vision and objectives, we will ensure that:

- Patients and their families receive outstanding support
- The charity continues to support the provision of cutting-edge clinical care and treatment through investment in advanced and innovative treatments
- We consider our donors and beneficiaries in everything we do
- We are accountable for how we spend our income and the impact it makes
- We strive for continuous development and improvement of our team and the support and experience we provide
- We help drive a change in attitudes amongst health care professionals and the public to generate optimism around PLANETS cancers and their treatment

Our goals

- 1) Improve patient outcomes: Longer survival and a better quality of life through early diagnosis and enhanced treatment conditions.
- 2) Better patient experience: Improved support, information communication and facilities for patients.
- 3) Assist the development of our centres: We can only achieve goals 1 and 2 by facilitating the development of our clinical teams and centres, so we can attract funding for clinical support, diagnosis, therapeutics and research.

Objectives and activities

PLANETS Cancer Charity helps patients with pancreatic, liver, colorectal, gastric, oesophageal and neuroendocrine cancer by funding patient support groups, innovative treatments, and research.

Public benefit

The trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities. The trustees refer to public benefit throughout this report.

ACHIEVEMENT AND PERFORMANCE - Charitable activities

Since our inception in 2011, PLANETS Cancer Charity has grown from a hospital charity fund into a fully independent organisation in 2019. Over the past 14 years, we've built a powerful and supportive community of patients, carers and healthcare professionals. Together, we've achieved more than many thought possible.

Our Key Achievements Include:

- **Building a Supportive Network**
We have established a network of patient support groups and hosted educational conferences across the Wessex region, focusing on pancreatic, colorectal, oesophageal, and neuroendocrine cancers.
- **Pioneering Intra-Operative Radiotherapy (IORT)**
We successfully fundraised £1 million to introduce the UK's first mobile electron beam radiotherapy machine. This revolutionary technology delivers radiotherapy during surgery to treat advanced cancers. It has already treated over 200 patients (as of December 2022) and is expected to benefit more than 2,000 over its lifespan. The treatment has significantly reduced recurrence rates and led to groundbreaking clinical outcomes published in top international medical journals.

- **Advancing Cancer Research**

We have funded full-time PhD and MD researchers in pancreatic and neuroendocrine tumours to work with clinician-scientists at the globally renowned Cancer Immunology Centre at the University of Southampton.

- **Achieving Centre of Excellence Status**

In 2016, we helped the Southampton, Portsmouth and Bournemouth/Poole region attain European Neuroendocrine Cancer Centre of Excellence status, reflecting world-class standards in patient care and clinical research.

- **Supporting Innovative Treatments**

We funded the introduction of **Hyperthermic Intraperitoneal Chemotherapy (HIPEC)** at University Hospital Southampton—one of the UK's first centres to offer this treatment, used to target cancers that have spread within the abdomen.

- **Employing a Dedicated Neuroendocrine Tumour Dietitian**


We funded one of the UK's first full-time specialist dietitians focused solely on neuroendocrine tumour patients, helping manage the significant digestive complications associated with these rare cancers. This Dietitian was reappointed through Direct Hospitals after 2 years and now works permanently across the Dorset and Hampshire region.

- **Revolutionising Surgical Planning with 3D Printing**

We funded a trial using 3D-printed liver models based on individual patients' CT scans. These personalised, anatomically precise models enable surgeons to better plan complex operations by visualising tumours and their proximity to vital structures. This innovation made Southampton the first UK centre to use this technology for liver cancer surgery—an initiative that garnered national media attention.

- **Improving Outcomes in Hilar Cholangiocarcinoma Surgery**

By converting CT and MRI scans into 3D models, we're supporting better preoperative planning for hilar cholangiocarcinoma, a bile duct cancer often deemed inoperable until exploratory surgery. These models allow surgeons to assess critical structures ahead of time, reducing the risk of irreversible surgical decisions and improving patient outcomes.



- **Creating a Dedicated Wellbeing Room for Liver Patients**

We funded the complete refurbishment of a new wellbeing room on Ward D9 at University Hospital Southampton. The space offers patients a calm environment for rest and private conversations, away from the clinical setting.

PLANETS contributed £12,000 towards the facility, which was made possible through a partnership with Taylor Wimpey Southern Counties—our 2023 Charity of the Year—which raised over £20,000.



- **Funding the REMACS Study**

We supported the **Reconstruction in Extended Margin Cancer Surgery (REMACS)** study, which investigates patient quality of life and cost-effectiveness following perineal reconstruction in abdominopelvic cancer cases.

- **Supporting a Wide Range of Small but Vital Projects**

We continue to invest in numerous smaller initiatives that make a big difference to patient care. These include:

- Ultrasound machines and radioisotope delivery equipment
- DAB radios for radiotherapy bunkers
- Psychotherapy sessions for patients struggling with a cancer diagnosis
- Personalised fitness programmes to support cancer recovery

Each of these projects, large or small, reflects our mission: to improve outcomes and enhance the experience of patients facing pancreatic, liver, colorectal, oesophageal, and neuroendocrine cancers.

This year, we proudly funded the following impactful projects:

- **Advancing Early Detection of Pancreatic Cancer**

We are supporting ongoing research into pancreatic cancer-associated diabetes, genetic variants, and metabolomic analysis using the UK Biobank cohort. This work aims to develop effective strategies for the early detection of pancreatic cancer—widely regarded as having the poorest survival outcomes among all cancers.

- **Acquisition of a Robotic Ultrasound Probe for the UHS HPB Team**

Ultrasound plays a critical role in hepatopancreatobiliary (HPB) surgery, and its importance is magnified in robotic procedures where tactile feedback is absent. It is essential for mapping lesion margins, assessing proximity to major vascular structures, evaluating liver blood flow, and detecting occult disease.

Unlike traditional laparoscopic ultrasound, robotic ultrasound enables the console surgeon to maintain full control—crucial for precision and patient safety. While UHS has already invested in one robotic HPB ultrasound probe, a second was urgently needed to support multiple cases on the same operating list, as current sterilisation turnaround times are insufficient. With the HPB robotic surgery service set to expand significantly over the next 12–24 months, this investment was both timely and strategic.

- **Cancer Coaching sessions** - This year, we were delighted to welcome Alison Bailey, Cancer Coach, to the PLANETS team. Her addition enhances the emotional and practical support we offer to patients and their families. Cancer coaching provides a safe, supportive space for individuals to talk through their current experiences and challenges, while equipping them with tools to set realistic, achievable life goals. These sessions empower people to regain a sense of control during an otherwise uncertain time. The coaching is entirely person-centred and tailored to the specific needs of each participant, ensuring meaningful and individualised support.

- **Improving Postoperative Recovery with Valley Cushions**

Following pelvic exenteration surgeries, patients with perineal wounds currently rely on makeshift support such as two pillows, typically introduced around day 10 post-operation. However, this solution often lacks stability and can increase the risk of wound breakdown—an outcome affecting up to 25% of patients, with significant implications for recovery time and morbidity. The Valley Cushion is purpose-designed to redistribute weight and offload pressure from the perineal area, thereby enhancing comfort and reducing the likelihood of wound complications.

- **Equipping Surgical Teams with New Theatre Caps**

We have provided new theatre caps to ensure our surgical teams maintain high hygiene standards while benefiting from increased comfort during procedures and improve communication pressured operating theatre settings where new members of the team may not remember everybody's name/role immediately.

- **Supporting Medical Training**

We continue to contribute towards the education and development of healthcare professionals through dedicated funding for medical training initiatives.

All of this has brought our local cancer community together.

In line with our charitable goals, all funds we raise are being channelled into new treatments that are directly saving lives, patient support initiatives which change the lives of those with cancer and research projects which may one day help us find new treatments such as immunotherapy for current and future patients.

Year in review – April 2024 to 31 March 2025

The last year has been one of consolidation, where we have been able to establish our funding priorities for the coming years by assessing a range of new projects and reevaluate our fundraising goals, in light of this. Although the overall fundraising climate remains challenging for UK charities due to national and international economic pressures, we have nonetheless been able to exceed our fundraising targets yet again. This has come about through a combination of individual donations and grants, fundraising events and successful grant applications. All of these have been very productive areas which have reflected positively on the success of our new staffing structure.

As a result, our balance sheet remains very healthy although we have significant ring-fenced funds for our new projects. We expect that over the next two years our reserve funds will probably reduce as we service these projects. Looking forward the prospects for the economic climate do not look good so we will need to prioritise grant applications and consider how best this may be achieved to ensure that we can continue to service our funding commitments.

Fundraising highlights have included our Dawn to Dusk cycle ride which raised over £66,000 and saw more than 50 riders of all levels of experience cycle from Winchester Cathedral to the Bristol Channel during the day. Our annual ball was held at the Grand in Southampton and was its usual success thanks to the extreme generosity of some of our auction prize donors. We have also had multiple small events including another tandem skydive, The Southsea Alternative Choir music gigs and a golf day.

We have been able to fund sessions from a cancer coach over the course of the year partly through successful grant applications. This is a new role which we will be evaluating to assess its long term value, in providing a different type of support for people living with cancer and their close relatives. In general the goal is to help individuals who are struggling with managing the diagnosis come to terms with it and find ways of developing coping strategies. These in turn enable them to feel more in control of their lives and as a result more able to balance the competing pressures that they face and live more rewarding and fruitful lives. The initial feedback is extremely positive and we are looking to continue this over the coming year.

Our Cancer Research projects continue to be productive, in particular we are looking to continue funding projects originally initiated by Liver and Pancreas Research and Development Fund also known as LAP R&D. This fund was transferred from Southampton Hospital Charity to PLANETS Cancer charity by mutual agreement in order to continue this project after the LAP R&D Fund founder, my former colleague Professor Mohammed Abu Hilal, moved abroad to work. At present this project is looking at data from the UK National Biobank to look for markers predicting development of pancreatic cancer. Early results are encouraging and we look forward to hearing more from this team.

Other areas of Cancer Research that we have continued to fund include evaluation of pelvic floor reconstruction following surgery for advanced cancers low in the pelvis. These results have been presented and published during this year and will help guide surgeons in future. A new area that we

have started to collaborate on is early research into a new group of potential chemotherapy agents which will work by attacking the mechanisms which allow cancer cells to spread. Normally chemotherapy works by interfering with the way tumour cells grow causing them to slow down or die.

The novel approach that we are exploring could have many applications including pancreatic, bowel and neuroendocrine cancers.

Our patient support groups have continued to expand into new areas, with the introduction of the first support group in the UK for patients recovering from complex pelvic floor surgery. This was very well attended by patients from across the country as well as those treated locally by our team of experts, led by PLANETS Trustee Professor Alex Mirnezami.

Over the course of the year one of our valued trustees Emily Medway asked to stand down and was replaced by Fergus Noble. I am extremely grateful to both for their commitment, help and service. Over the coming year we will look to further refresh and strengthen our Board of Trustees in order to continue to vigorously support our charitable objectives.

As always I am extremely grateful to our staff, trustees, patron, ambassadors and many supporters who continue to enable our charity to put the icing on the cake and maintain the strength of cancer care provision, patient support and research within the central South Coast area.

Neil Pearce - July 2025



Media Activity - April 2024 to April 2025

Over the course of this period, we recorded 190 items of coverage with an audience reach of 120 to 150 million impressions across national, regional and syndicated (news wire) media coverage.



Some of the stories which we have published in the media this year include:

May 2024

PLANETS hailed the decision to make an innovative and targeted radiotherapy treatment available on the NHS for patients with neuroendocrine tumours (NETs) in the liver.

We ran a press release urgently requesting a change in NHS commissioning that would allow patients equal access to Selective Internal Radiation Therapy (SIRT) for neuroendocrine tumours (NETs) that have spread to the liver.

It is currently only funded for NHS patients with primary liver cancer and colorectal cancer which has spread to the liver – despite the recent publication of NICE guidance which recommends SIRT as a standard treatment option for NET patients.

Funding this treatment would significantly improve outcomes for our patients and enhance the quality of care available across the UK.

June 2024

In June we raised an incredible £66,000 + at our 'Dawn to Dusk' cycle challenge - £10,000 over target.

Jo Green, director of operations and marketing for PLANETS who is a neuroendocrine cancer patient and participated in the 100-mile challenge, said: "We are immensely proud of what our patients, clinicians, supporters and sponsors achieved through our Dawn to Dusk challenge and cannot thank everyone enough – it truly was epic.

"We had a total of 54 participants aged from 15 to 74 who all made it through the 100 miles and who all played their part in securing £60,000 for the charity which will prove vital to the work we do for cancer patients.

“We all feel extremely fortunate to have shared this amazing experience with so many brilliant people and it really shows what can be achieved when people come together, not just in terms of fundraising but also the friendships and bonds created along the way.”



July 2024

PLANETS called on the government to intervene urgently over the shortage of a drug that can prevent life-threatening digestive problems in thousands of people with a range of medical conditions..

The treatment is often referred to as Creon which is the brand name of a commonly-used type of the drug. PERT is prescribed for patients with pancreatic deficiencies caused by a variety of conditions including pancreatic cancer, pancreatic surgery, cystic fibrosis, chronic pancreatitis and neuroendocrine tumours.

Patients who rely on the medication suffer severe abdominal cramps and a particularly unpleasant form of diarrhoea when they are unable to obtain it – typically taking a handful of the tablets with every meal to avoid these symptoms.

Lack of adequate PERT leads to malnutrition, with rapid weight loss, fatigue, vitamin and mineral deficiency, susceptibility to infections and, as many of these patients are diabetic, their blood sugars become increasingly difficult to control.

The shortage has been caused by a number of factors including supply chain issues across Europe exacerbated by leaving the European Union, the lack of a UK manufacturer and a worldwide increase in demand due to a rise in the number of patients living with the conditions related to it.

August 2024

In August we issues further coverage of our campaign to improve travel insurance cost and cover for cancer patients.

change.org



Petition details

Comments



Ensure cancer patients are able to access affordable travel insurance

Started

5 July 2022

Petition to

[Financial Conduct Authority](#)

133,612

Signatures

150,000

Next Goal

September 2024

In September some of our patients from across the south, their clinicians and family members raised more than £9,500 by leaping from Europe's largest drop zone




October 2024

We reported that our UHS researchers funded by PLANETS found taking aspirin regularly cuts the risk of developing pancreatic cancer by 40% in people with diabetes – and by 20% in the general population.



February 2025

Research published in the journal Cancers and part-funded by PLANETS found patients with complex cancers of the abdomen and pelvis which were previously deemed inoperable are now surviving long-term thanks to developments in surgical techniques and expertise.



FINANCIAL REVIEW

Financial position

The Charity's financial position as of 31 March 2025 can be found in the Balance Sheet. As of 31 March 2025 the charity bank balance was £317,055 (plus £85,311, 85,000 and £89,163) in three high interest savings accounts). The charity generated income of £378,022 for the period from 1 April 2024 to 31 March 2025.

At the beginning of the financial year we had £205,130 ring fenced to go towards funding Research and Development Projects.

This year, PLANETS Cancer Charity funded several impactful initiatives:

- **Pancreatic Cancer Research**

We supported ongoing studies using UK Biobank data to improve early detection of pancreatic cancer, one of the deadliest cancer types.

- **Robotic Ultrasound Probe for HPB Surgery**

We funded a second robotic ultrasound probe for UHS to enhance precision in complex HPB surgeries, supporting the growth of the robotic surgery service.

- **Valley Cushions for Postoperative Recovery**

We provided specialist cushions to improve comfort and reduce wound complications in patients recovering from pelvic exenteration surgeries.

- **Theatre Caps for Surgical Teams**

We supplied new surgical caps to promote hygiene and comfort in operating theatres.

- **Medical Training Support**

We continued to invest in training and professional development for healthcare staff.

- **Patient Support** - We also funded numerous patient support days and conferences.

The Charity will continue to operate normally for a period of at least 12 months from the date of approval of the financial statements.

FINANCIAL REVIEW - Reserves policy

For **2024/25** the Charity's reserves policy, which is reviewed each year, was to retain an amount of

unrestricted reserves which was enough to cover 1 year of governance, management, fundraising and administration. We aim to spend income within 36 months of receipt. Where sums are set aside towards the cost of a project or piece of equipment, we ring fence those sums until enough money is available to meet the full cost of the project.

Help Us Raise £2 Million to Transform Cancer Care Over the Next Five Years

To meet our ambitious goals, we must raise **£2 million** over the next five years. This vital funding will enable us to provide:

- **£250,000** for direct patient support
- **£500,000** to advance research into PLANETS cancers
- **£750,000** for cutting-edge, innovative treatments

We are also committed to keeping our administrative costs below 25% of total turnover, ensuring your donations deliver the greatest possible impact.

In today's cost-conscious NHS environment, research and innovation are under threat. At PLANETS, we are determined to ensure that patients across our region—and beyond—continue to receive world-leading care and access to the latest treatments.

Your support will help us fund several critical initiatives, including:

- **The REMACS Study**

We are co-funding a PhD researcher in this important national study, focused on quality of life and outcome measures following various surgical techniques for advanced pelvic cancers such as recurrent rectal cancer.

- **Predictive Models for Pancreatic Cancer**

We're supporting research into genomic and clinical risk factors to predict those most at risk of developing pancreatic cancer. This includes funding laboratory costs for a dedicated PhD researcher using data from cancer patients and the UK Biobank.

- **Upper GI Cancer Network Data Controller (50% funded)**

Launched in January 2025, this 3-year project represents a significant step forward in strengthening the quality, consistency, and security of data collection within the Upper GI cancer network. The initiative is 50% funded by PLANETS Charity and reflects our ongoing commitment to advancing both clinical care and research across the region. The project will support the appointment of a dedicated **Data Controller**, who will play a pivotal role in managing cancer data across multiple trusts, ensuring it is collected, stored, and shared in a secure, standardised, and ethically compliant manner. By improving data accuracy and accessibility, this role will directly enhance patient care, clinical decision-making, and outcomes tracking. This is a **collaborative initiative** between **Dorset County Hospital, Portsmouth Hospitals University NHS Trust, and University Hospital Southampton**, designed to foster data integration and knowledge-sharing across institutions. Ultimately, the project aims to lay the foundation for a robust, region-wide Upper GI cancer dataset that can inform both local service improvements and national research priorities.

- **Development and testing of a new drug class in Pancreatic, Liver, and Neuroendocrine cancers.** Cancer remains one of the greatest medical challenges, with spread of the cancer (metastasis) and resistance to drug treatment (chemotherapy resistance) representing two of the main causes of cancer related death. We have previously showed that most cancers activate a key biological process called epithelial-mesenchymal transition (EMT) which leads to cancer spread and drug resistance, and that targeting this pathway can lead to cancer cell death. However, existing drugs that target this pathway have high toxicity. By collaborating with the Chemistry department at the University of Southampton, through a EPSRC research grant, we have now developed four novel compounds targeting this pathway that can kill Neuroendocrine, Hepatocellular and Pancreatic cancer but induce no harm in normal cells
- **Jet Vent Machine**
This advanced technology enables prolonged breath-hold techniques (60–90 minutes), significantly expanding the range and complexity of our liver ablation services, allowing us to treat more—and more complex—cases.
- **Da Vinci Robotic Surgery Console**
Funding a new Da Vinci surgical console will double the number of PLANETS cancer patients receiving minimally invasive robotic surgery at the regional cancer centre in Southampton. This will also help us establish UHS as a national training hub for robotic cancer surgery.

Why It Matters

Each of these projects represents a leap forward in **patient care**, **scientific understanding**, and **clinical innovation**. But none of it is possible without the generosity of people like you.

**Join us in shaping the future of cancer care.
Together, we can save lives.**



STRUCTURE, GOVERNANCE AND MANAGEMENT - Governing document

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

PLANETS is a Foundation Charitable Incorporated Organisation (CIO) and is governed in accordance with its constitution. The only members of the CIO shall be those persons who are appointed as Trustees of the CIO, and all persons appointed as Trustees shall be admitted as members. Membership cannot be transferred to anyone else. A member shall cease to be a member immediately that he or she ceases to be a Trustee of the CIO for any reason.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number - 1175572

Principal address - Milestone Cottage, 113 Havant Rd, Emsworth, Hampshire, PO10 7LG

Chairman of trustees - Mr Neil Pearce

Trustees

Dr B Stedman

Professor A Mirnezami

Dr F Noble

Mr C Hoyland

Miss V Caine


Miss R M H Willrich

Independent Examiner

S Mackie, FCA, Morris Crocker, Chartered Accountants

Station House, North Street, Havant, Hampshire, PO9 1QU

Approved by order of the board of trustees on 31st October 2025
and signed on its behalf by:

A handwritten signature in black ink, appearing to read 'Dr B Stedman', is shown on a light grey background.

Dr B Stedman - Trustee

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF PLANETS CANCER CHARITY

Independent examiner's report to the trustees of Planets Cancer Charity

I report to the charity trustees on my examination of the accounts of Planets Cancer Charity (the Trust) for the year ended 31 March 2025.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Stuart Mackie

S Mackie, FCA

Morris Crocker
Chartered Accountants
Station House
North Street
Havant
Hampshire
PO9 1QU

Date: 11/11/25.....

PLANETS CANCER CHARITY

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2025**

	Notes	Unrestricted funds £	Restricted funds £	2025 Total funds £	2024 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	141,221	128,224	269,445	363,955
Charitable activities	5				
Charitable activities		124	-	124	80
Other trading activities	3	103,958	-	103,958	55,852
Investment income	4	<u>4,495</u>	<u>-</u>	<u>4,495</u>	<u>9</u>
Total		<u>249,798</u>	<u>128,224</u>	<u>378,022</u>	<u>419,896</u>
 EXPENDITURE ON					
Raising funds	6	37,693	-	37,693	28,739
Charitable activities	7				
Charitable activities		<u>179,866</u>	<u>25,194</u>	<u>205,060</u>	<u>208,025</u>
Total		<u>217,559</u>	<u>25,194</u>	<u>242,753</u>	<u>236,764</u>
 NET INCOME		32,239	103,030	135,269	183,132
 RECONCILIATION OF FUNDS					
Total funds brought forward		<u>458,373</u>	<u>5,130</u>	<u>463,503</u>	<u>280,371</u>
 TOTAL FUNDS CARRIED FORWARD		<u><u>490,612</u></u>	<u><u>108,160</u></u>	<u><u>598,772</u></u>	<u><u>463,503</u></u>

The notes form part of these financial statements


PLANETS CANCER CHARITY

BALANCE SHEET 31 MARCH 2025

	Notes	2025 £	2024 £
CURRENT ASSETS			
Stocks	12	3,558	4,339
Debtors	13	21,024	-
Cash at bank		<u>576,550</u>	<u>460,617</u>
		601,132	464,956
CREDITORS			
Amounts falling due within one year	14	(2,360)	(1,453)
		<u>598,772</u>	<u>463,503</u>
NET CURRENT ASSETS			
		<u>598,772</u>	<u>463,503</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			
		<u>598,772</u>	<u>463,503</u>
NET ASSETS			
		<u>598,772</u>	<u>463,503</u>
FUNDS	16		
Unrestricted funds		490,612	458,373
Restricted funds		<u>108,160</u>	<u>5,130</u>
TOTAL FUNDS		<u>598,772</u>	<u>463,503</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 10 November 2025 and were signed on its behalf by:

B Stedman - Trustee



The notes form part of these financial statements

PLANETS CANCER CHARITY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

The trustees consider that there are no material uncertainties about the Charity's ability to continue as a going concern.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease.

Financial instruments

The charity only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable investments in stocks and shares. The measurement basis used for these instruments is detailed below.

Debtors and cash at bank

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due. Cash at bank and in hand included cash held on deposit or in a current account.

PLANETS CANCER CHARITY

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

1. ACCOUNTING POLICIES - continued

Financial instruments

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

2. DONATIONS AND LEGACIES

	2025	2024
	£	£
Donations	159,421	129,168
Legacies	-	33,949
Ring-fenced Donations - R&D	23,024	838
Ring fenced donations - Grange /R&D	-	200,000
Ring-fenced Donations - Robotics Project	25,000	-
Ring-fenced Donations - UGI Data Project	<u>62,000</u>	<u>-</u>
	<u>269,445</u>	<u>363,955</u>

3. OTHER TRADING ACTIVITIES

	2025	2024
	£	£
Fundraising events	<u>103,958</u>	<u>55,852</u>

4. INVESTMENT INCOME

	2025	2024
	£	£
Deposit account interest	<u>4,495</u>	<u>9</u>

All investment income is derived from assets held in the United Kingdom.

5. INCOME FROM CHARITABLE ACTIVITIES

	2025	2024
	£	£
Merchandising	<u>124</u>	<u>80</u>
Activity		
Charitable activities		

PLANETS CANCER CHARITY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025**

6. RAISING FUNDS

Raising donations and legacies

	2025 £	2024 £
Fundraising expenditure	<u>37,693</u>	<u>28,739</u>

7. CHARITABLE ACTIVITIES COSTS

	Direct Costs £	Support costs (see note 8) £	Totals £
Charitable activities	<u>192,045</u>	<u>13,015</u>	<u>205,060</u>

8. SUPPORT COSTS

	Management £	Finance £	Governance costs £	Totals £
Charitable activities	<u>8,120</u>	<u>276</u>	<u>4,619</u>	<u>13,015</u>

Support costs, included in the above, are as follows:

Management

	2025 Charitable activities £	2024 Total activities £
Computer costs	6,991	5,356
Training costs	-	945
Postage and stationery	<u>1,129</u>	<u>940</u>
	<u>8,120</u>	<u>7,241</u>

Finance

	2025 Charitable activities £	2024 Total activities £
Bank charges	<u>276</u>	<u>168</u>

Governance costs

	2025 Charitable activities £	2024 Total activities £
Professional fee	1,394	1,051
Trustee meeting expenses	1,104	957
Accountancy	1,509	1,386
Payroll	<u>612</u>	<u>487</u>
	<u>4,619</u>	<u>3,881</u>

PLANETS CANCER CHARITY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025**

9. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 March 2025 nor for the year ended 31 March 2024.

Trustees' expenses

During the year no trustees (2024: none) were reimbursed out of pocket expenses totalling £nil (2024: £nil).

10. STAFF COSTS

No employees received emoluments in excess of £60,000.

The key management personnel of the charity comprise the Operations Director, Chief Executive and Fundraising Officer with remuneration totalling £119,617 for 2025 (2024: £121,704).

11. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	363,117	838	363,955
Charitable activities			
Charitable activities	80	-	80
Other trading activities	55,852	-	55,852
Investment income	<u>9</u>	<u>-</u>	<u>9</u>
Total	<u>419,058</u>	<u>838</u>	<u>419,896</u>
EXPENDITURE ON			
Raising funds	28,739	-	28,739
Charitable activities			
Charitable activities	<u>195,215</u>	<u>12,810</u>	<u>208,025</u>
Total	<u>223,954</u>	<u>12,810</u>	<u>236,764</u>
NET INCOME/(EXPENDITURE)	195,104	(11,972)	183,132
RECONCILIATION OF FUNDS			
Total funds brought forward	<u>263,269</u>	<u>17,102</u>	<u>280,371</u>
TOTAL FUNDS CARRIED FORWARD	<u>458,373</u>	<u>5,130</u>	<u>463,503</u>

PLANETS CANCER CHARITY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025**

12. STOCKS

	2025	2024
	£	£
Stocks	<u>3,558</u>	<u>4,339</u>

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025	2024
	£	£
Trade debtors	<u>21,024</u>	<u>-</u>

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025	2024
	£	£
Other creditors	<u>2,360</u>	<u>1,453</u>

15. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted funds £	Restricted funds £	2025 Total funds £	2024 Total funds £
Current assets	492,972	108,160	601,132	464,956
Current liabilities	<u>(2,360)</u>	<u>-</u>	<u>(2,360)</u>	<u>(1,453)</u>
	<u>490,612</u>	<u>108,160</u>	<u>598,772</u>	<u>463,503</u>

16. MOVEMENT IN FUNDS

	At 1.4.24 £	Net movement in funds £	At 31.3.25 £
Unrestricted funds			
General fund	258,373	32,239	290,612
Grange donation	<u>200,000</u>	<u>-</u>	<u>200,000</u>
	458,373	32,239	490,612
Restricted funds			
R&D fund	5,130	(2,170)	2,960
Robotics Project	-	25,000	25,000
UGI Data Project	-	62,000	62,000
Patient Support	<u>-</u>	<u>18,200</u>	<u>18,200</u>
	<u>5,130</u>	<u>103,030</u>	<u>108,160</u>
TOTAL FUNDS	<u>463,503</u>	<u>135,269</u>	<u>598,772</u>

PLANETS CANCER CHARITY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025**

16. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	249,798	(217,559)	32,239
Restricted funds			
R&D fund	23,024	(25,194)	(2,170)
Robotics Project	25,000	-	25,000
UGI Data Project	62,000	-	62,000
Patient Support	18,200	-	18,200
	<u>128,224</u>	<u>(25,194)</u>	<u>103,030</u>
TOTAL FUNDS	<u>378,022</u>	<u>(242,753)</u>	<u>135,269</u>

Comparatives for movement in funds

	At 1.4.23 £	Net movement in funds £	At 31.3.24 £
Unrestricted funds			
General fund	263,269	(4,896)	258,373
Grange donation	-	200,000	200,000
	263,269	195,104	458,373
Restricted funds			
R&D fund	17,102	(11,972)	5,130
	<u>280,371</u>	<u>183,132</u>	<u>463,503</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	219,058	(223,954)	(4,896)
Grange donation	200,000	-	200,000
	419,058	(223,954)	195,104
Restricted funds			
R&D fund	838	(12,810)	(11,972)
	<u>419,896</u>	<u>(236,764)</u>	<u>183,132</u>

REMACS R&D - reconstruction in extended margin cancer surgery (REMACS) pancreatic cancer research and development and model trial.

PLANETS CANCER CHARITY

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

16. MOVEMENT IN FUNDS - continued

Grange donation - Monies donated to be put towards suggested items by the donor but with ultimate discretion as to amounts, items and timing left to the trustees to maximise the donation.

Robotics Project - The project proposed is the acquisition of a new Da Vinci XI robot platform, to join the existing robotic fleet of 1 Da Vinci X (older model), 1 Da Vinci XI (the same as this one) and 1 CMR Robot. The current Da Vinci platforms are nearing 100% utilisation amongst colorectal, thoracic surgery, HPB surgery, Upper GI Surgery and Urology. This means that there are many patients in these specialities (approximately the same number as are currently being treated with robotic surgery) that could benefit from the enhanced clinical outcomes that robotic surgery can offer, particularly for those patients who can currently only be offered open surgery.

UGI Data Project - To enable dedicated and consistent, accurate, timely and secure data acquisition from clinical and basic/translational science sources building upon the existing successful infrastructure in the ITRG. We will extend data acquisition from UHS/UoS to include Portsmouth and Bournemouth patients.

Patient Support - Patient support groups for our patients covering each cancer type that PLANETS manage. This is covering patients in the Dorset and Hampshire areas (and beyond) and includes Cancer coaching , conferences and coffee mornings.

17. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 March 2025.